HHLR Advisors’s Regenxbio RGNX Stock Holding History

HHLR Advisors’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-456,000	Closed	-$14.9M	–	76
2021 Q4	$14.9M	Hold	456,000	–	–	0.23%	41
2021 Q3	$19.1M	Hold	456,000	–	–	0.25%	44
2021 Q2	$17.7M	Hold	456,000	–	–	0.18%	55
2021 Q1	$15.6M	Hold	456,000	–	–	0.15%	53
2020 Q4	$20.7M	Hold	456,000	–	–	0.16%	57
2020 Q3	$12.5M	Hold	456,000	–	–	0.1%	57
2020 Q2	$16.8M	Hold	456,000	–	–	0.15%	48
2020 Q1	$14.8M	Hold	456,000	–	–	0.2%	39
2019 Q4	$18.7M	Hold	456,000	–	–	0.23%	37
2019 Q3	$16.2M	Buy	456,000 +250,000	+121%	+$10.1M	0.22%	45
2019 Q2	$10.6M	Buy	+206,000	New	+$10.3M	0.24%	34

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HHLR Advisors's RGNX Position: Q1 2022 in Review

HHLR Advisors sold out of Regenxbio (RGNX) in Q1 2022, closing a stake of 456,000 shares — an estimated $14.9M sold.

HHLR Advisors first reported a position in RGNX in Q2 2019 and held it in 11 quarters. The position peaked at $20.7M in Q4 2020. 188 funds tracked by Wall St. Rank hold RGNX as of Q1 2022.

HHLR Advisors reported no remaining Regenxbio position as of Q1 2022 after selling out during the quarter.
HHLR Advisors sold 456,000 Regenxbio shares in Q1 2022, an estimated $14.9M.
HHLR Advisors first reported a position in Regenxbio in Q2 2019 and held it in 11 quarters.
HHLR Advisors's Regenxbio position peaked at $20.7M in Q4 2020.
188 funds tracked by Wall St. Rank held Regenxbio as of Q1 2022.

Based on HHLR Advisors's 13F filing for Q1 2022, filed 16 May 2022.